References

2.

Afkarian

M

,

Sachs

MC

,

Kestenbaum

B

, et al

Kidney disease and increased mortality risk in type 2 diabetes

.

J Am Soc Nephrol

2013

;

24

:

302

–

308

3.

Brenner

BM

,

Cooper

ME

,

de Zeeuw

D

, et al;

RENAAL Study Investigators

.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

.

N Engl J Med

2001

;

345

:

861

–

869

4.

Lewis

EJ

,

Hunsicker

LG

,

Clarke

WR

, et al;

Collaborative Study Group

.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

.

N Engl J Med

2001

;

345

:

851

–

860

5.

Wanner

C

,

Inzucchi

SE

,

Lachin

JM

, et al;

EMPA-REG OUTCOME Investigators

.

Empagliflozin and progression of kidney disease in type 2 diabetes

.

N Engl J Med

2016

;

375

:

323

–

334

6.

Heerspink

HJL

,

Desai

M

,

Jardine

M

,

Balis

D

,

Meininger

G

,

Perkovic

V

.

Canagliflozin slows progression of renal function decline independently of glycemic effects

.

J Am Soc Nephrol

2017

;

28

:

368

–

375

7.

Marso

SP

,

Bain

SC

,

Consoli

A

, et al;

SUSTAIN-6 Investigators

.

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

.

N Engl J Med

2016

;

375

:

1834

–

1844

8.

Perkovic

V

,

Jardine

MJ

,

Neal

B

, et al;

CREDENCE Trial Investigators

.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

.

N Engl J Med

2019

;

380

:

2295

–

2306

9.

Bakris

GL

,

Agarwal

R

,

Anker

SD

, et al;

FIDELIO-DKD Investigators

.

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes

.

N Engl J Med

2020

;

383

:

2219

–

2229

10.

White

KE

,

Bilous

RW

.

Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease

.

J Am Soc Nephrol

2000

;

11

:

1667

–

1673

11.

Sheetz

MJ

,

King

GL

.

Molecular understanding of hyperglycemia's adverse effects for diabetic complications

.

JAMA

2002

;

288

:

2579

–

2588

12.

Vallon

V

,

Komers

R

.

Pathophysiology of the diabetic kidney

.

Compr Physiol

2011

;

1

:

1175

–

1232

13.

Sorbinil Retinopathy Trial Research Group

.

A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy

.

Arch Ophthalmol

1990

;

108

:

1234

–

1244

14.

Schleicher

ED

,

Weigert

C

.

Role of the hexosamine biosynthetic pathway in diabetic nephropathy

.

Kidney Int Suppl

2000

;

77

:

S13

–

S18

15.

Tuttle

KR

,

Bakris

GL

,

Toto

RD

,

McGill

JB

,

Hu

K

,

Anderson

PW

.

The effect of ruboxistaurin on nephropathy in type 2 diabetes

.

Diabetes Care

2005

;

28

:

2686

–

2690

16.

Tonneijck

L

,

Muskiet

MH

,

Smits

MM

, et al

Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment

.

J Am Soc Nephrol

2017

;

28

:

1023

–

1039

17.

Brenner

BM

,

Lawler

EV

,

Mackenzie

HS

.

The hyperfiltration theory: a paradigm shift in nephrology

.

Kidney Int

1996

;

49

:

1774

–

1777

18.

Cooper

ME

,

Vranes

D

,

Youssef

S

, et al

Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes

.

Diabetes

1999

;

48

:

2229

–

2239

19.

Gnudi

L

.

Angiopoietins and diabetic nephropathy

.

Diabetologia

2016

;

59

:

1616

–

1620

20.

Bohle

A

,

Wehrmann

M

,

Bogenschutz

O

,

Batz

C

,

Müller

CA

,

Müller

GA

.

The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis

.

Pathol Res Pract

1991

;

187

:

251

–

259

21.

Nguyen

D

,

Ping

F

,

Mu

W

,

Hill

P

,

Atkins

RC

,

Chadban

SJ

.

Macrophage accumulation in human progressive diabetic nephropathy

.

Nephrology (Carlton)

2006

;

11

:

226

–

231

22.

Yonemoto

S

,

Machiguchi

T

,

Nomura

K

,

Minakata

T

,

Nanno

M

,

Yoshida

H

.

Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus

.

Clin Exp Nephrol

2006

;

10

:

186

–

192

23.

Tesch

GH

.

Macrophages and diabetic nephropathy

.

Semin Nephrol

2010

;

30

:

290

–

301

24.

Bertocchio

JP

,

Warnock

DG

,

Jaisser

F

.

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease

.

Kidney Int

2011

;

79

:

1051

–

1060

25.

Yu

SM

,

Bonventre

JV

.

Acute kidney injury and progression of diabetic kidney disease

.

Adv Chronic Kidney Dis

2018

;

25

:

166

–

180

26.

Kinsey

GR

.

Macrophage dynamics in AKI to CKD progression

.

J Am Soc Nephrol

2014

;

25

:

209

–

211

27.

Barrera-Chimal

J

,

Estrela

GR

,

Lechner

SM

, et al

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

.

Kidney Int

2018

;

93

:

1344

–

1355

28.

Wang

Y

,

Harris

DC

.

Macrophages in renal disease

.

J Am Soc Nephrol

2011

;

22

:

21

–

27

29.

Calle

P

,

Hotter

G

.

Macrophage phenotype and fibrosis in diabetic nephropathy

.

Int J Mol Sci

2020

;

21

:

2806

30.

Flyvbjerg

A

.

The role of the complement system in diabetic nephropathy

.

Nat Rev Nephrol

2017

;

13

:

311

–

318

31.

Østergaard

J

,

Thiel

S

,

Gadjeva

M

,

Hansen

TK

,

Rasch

R

,

Flyvbjerg

A

.

Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice

.

Diabetologia

2007

;

50

:

1541

–

1549

32.

Hansen

TK

,

Forsblom

C

,

Saraheimo

M

, et al

Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes

.

Diabetologia

2010

;

53

:

1517

–

1524

33.

Østergaard

JA

,

Thiel

S

,

Hovind

P

, et al

Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study

.

Diabetologia

2014

;

57

:

2201

–

2207

34.

Falk

RJ

,

Dalmasso

AP

,

Kim

Y

, et al

Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and immunohistochemical localization in renal disease

.

J Clin Invest

1983

;

72

:

560

–

573

35.

Falk

RJ

,

Scheinman

JI

,

Mauer

SM

,

Michael

AF

.

Polyantigenic expansion of basement membrane constituents in diabetic nephropathy

.

Diabetes

1983

;

32

(

Suppl. 2

):

34

–

39

36.

Falk

RJ

,

Sisson

SP

,

Dalmasso

AP

,

Kim

Y

,

Michael

AF

,

Vernier

RL

.

Ultrastructural localization of the membrane attack complex of complement in human renal tissues

.

Am J Kidney Dis

1987

;

9

:

121

–

128

37.

Riser

BL

,

Denichilo

M

,

Cortes

P

, et al

Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis

.

J Am Soc Nephrol

2000

;

11

:

25

–

38

38.

Tervaert

TW

,

Mooyaart

AL

,

Amann

K

, et al

Pathologic classification of diabetic nephropathy

.

J Am Soc Nephrol

2010

;

21

:

556

–

563

39.

Perrin

NE

,

Torbjörnsdotter

TB

,

Jaremko

GA

,

Berg

UB

.

Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes

.

Pediatr Nephrol

2004

;

19

:

1004

–

1013

40.

Drummond

K

,

Mauer

M

;

International Diabetic Nephropathy Study Group

.

The early natural history of nephropathy in type 1 diabetes: II. early renal structural changes in type 1 diabetes

.

Diabetes

2002

;

51

:

1580

–

1587

41.

Kim

Y

,

Kleppel

MM

,

Butkowski

R

,

Mauer

SM

,

Wieslander

J

,

Michael

AF

.

Differential expression of basement membrane collagen chains in diabetic nephropathy

.

Am J Pathol

1991

;

138

:

413

–

420

42.

Dominguez

JH

,

Tang

N

,

Xu

W

, et al

Studies of renal injury III: lipid-induced nephropathy in type II diabetes

.

Kidney Int

2000

;

57

:

92

–

104

43.

Stratton

IM

,

Adler

AI

,

Neil

HA

, et al

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

.

BMJ

2000

;

321

:

405

–

412

44.

Rossing

K

,

Christensen

PK

,

Hovind

P

,

Tarnow

L

,

Rossing

P

,

Parving

H-H

.

Progression of nephropathy in type 2 diabetic patients

.

Kidney Int

2004

;

66

:

1596

–

1605

45.

UK Prospective Diabetes Study Group

.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

.

Lancet

1998

;

352

:

837

–

853

46.

Holman

RR

,

Paul

SK

,

Bethel

MA

,

Matthews

DR

,

Neil

HA

.

10-year follow-up of intensive glucose control in type 2 diabetes

.

N Engl J Med

2008

;

359

:

1577

–

1589

47.

Curovic

VR

,

Theilade

S

,

Winther

SA

, et al

Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes

.

Diabet Med

.

Online ahead of print on 11 November 2020 (doi: 10.1111/dme.14459)

48.

Hsu

CC

,

Chang

HY

,

Huang

MC

, et al

HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study

.

Diabetologia

2012

;

55

:

3163

–

3172

49.

ADVANCE Collaborative Group

;

Patel

A

,

MacMahon

S

,

Chalmers

J

, et al

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

.

N Engl J Med

2008

;

358

:

2560

–

2572

50.

Perkovic

V

,

Heerspink

HL

,

Chalmers

J

, et al;

ADVANCE Collaborative Group

.

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

.

Kidney Int

2013

;

83

:

517

–

523

51.

Mann

JFE

,

Ørsted

DD

,

Brown-Frandsen

K

, et al;

LEADER Steering Committee and Investigators

.

Liraglutide and renal outcomes in type 2 diabetes

.

N Engl J Med

2017

;

377

:

839

–

848

52.

Gerstein

HC

,

Colhoun

HM

,

Dagenais

GR

, et al;

REWIND Investigators

.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

.

Lancet

2019

;

394

:

131

–

138

53.

Heerspink

HJL

,

Stefánsson

BV

,

Correa-Rotter

R

, et al.

DAPA-CKD Trial Committees and Investigators

.

Dapagliflozin in patients with chronic kidney disease

.

N Engl J Med

2020

;

383

:

1436

–

1446

54.

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

.

J Hypertens

1993

;

11

:

309

–

317

55.

Retnakaran

R

,

Cull

CA

,

Thorne

KI

,

Adler

AI

,

Holman

RR

;

UKPDS Study Group

.

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74

.

Diabetes

2006

;

55

:

1832

–

1839

56.

Nørgaard

K

,

Feldt-Rasmussen

B

,

Borch-Johnsen

K

,

Saelan

H

,

Deckert

T

.

Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus

.

Diabetologia

1990

;

33

:

407

–

410

57.

McMullan

CJ

,

Heerspink

HJL

,

Parving

H-H

,

Dwyer

JP

,

Forman

JP

,

de Zeeuw

D

.

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial

.

Am J Kidney Dis

2014

;

64

:

714

–

722

58.

Parving

H-H

,

Lehnert

H

,

Brochner-Mortensen

J

,

Gomis

R

,

Andersen

S

,

Arner

P

.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

.

N Engl J Med

2001

;

345

:

870

–

878

59.

Persson

F

,

Lindhardt

M

,

Rossing

P

,

Parving

H-H

.

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review

.

J Renin Angiotensin Aldosterone Syst

2016

;

17

:

1470320316652047

60.

Peti-Peterdi

J

.

High glucose and renin release: the role of succinate and GPR91

.

Kidney Int

2010

;

78

:

1214

–

1217

61.

Frimodt-Moller

M

,

Persson

F

,

Rossing

P

.

Mitigating risk of aldosterone in diabetic kidney disease

.

Curr Opin Nephrol Hypertens

2020

;

29

:

145

–

151

62.

Hsu

CY

,

McCulloch

CE

,

Iribarren

C

,

Darbinian

J

,

Go

AS

.

Body mass index and risk for end-stage renal disease

.

Ann Intern Med

2006

;

144

:

21

–

28

63.

Krikken

JA

,

Bakker

SJ

,

Navis

GJ

.

Role of renal haemodynamics in the renal risks of overweight

.

Nephrol Dial Transplant

2009

;

24

:

1708

–

1711

64.

Sharma

K

.

The link between obesity and albuminuria: adiponectin and podocyte dysfunction

.

Kidney Int

2009

;

76

:

145

–

148

65.

Bjornstad

P

,

Nehus

E

,

Jenkins

T

, et al

Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes

.

Kidney Int

2020

;

97

:

995

–

1005

66.

Scirica

BM

,

Bohula

EA

,

Dwyer

JP

, et al;

CAMELLIA-TIMI 61 Steering Committee and Investigators

.

Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial

.

Circulation

2019

;

139

:

366

–

375

67.

von Scholten

BJ

,

Persson

F

,

Svane

MS

,

Hansen

TW

,

Madsbad

S

,

Rossing

P

.

Effect of large weight reductions on measured and estimated kidney function

.

BMC Nephrol

2017

;

18

:

52

68.

Daousi

C

,

Bain

SC

,

Barnett

AH

,

Gill

GV

.

Hypertriglyceridaemia is associated with an increased likelihood of albuminuria in extreme duration (> 50 years) type 1 diabetes

.

Diabet Med

2008

;

25

:

1234

–

1236

69.

Hovind

P

,

Rossing

P

,

Tarnow

L

,

Smidt

UM

,

Parving

H-H

.

Progression of diabetic nephropathy

.

Kidney Int

2001

;

59

:

702

–

709

70.

Thomas

MC

,

Rosengard-Barlund

M

,

Mills

V

, et al

Serum lipids and the progression of nephropathy in type 1 diabetes

.

Diabetes Care

2006

;

29

:

317

–

322

71.

Tolonen

N

,

Forsblom

C

,

Thorn

L

, et al;

FinnDiane Study Group

.

Relationship between lipid profiles and kidney function in patients with type 1 diabetes

.

Diabetologia

2008

;

51

:

12

–

20

72.

Tofte

N

,

Suvitaival

T

,

Ahonen

L

, et al

Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes

.

Sci Rep

2019

;

9

:

16398

73.

Hsu

CC

,

Chang

HY

,

Huang

MC

, et al

Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study

.

Diabetes Care

2011

;

34

:

982

–

987

74.

Thorn

LM

,

Forsblom

C

,

Waden

J

, et al;

Finnish Diabetic Nephropathy (FinnDiane) Study Group

.

Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes

.

Diabetes Care

2009

;

32

:

950

–

952

75.

Kilpatrick

ES

,

Rigby

AS

,

Atkin

SL

.

Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial

.

Diabetes Care

2007

;

30

:

707

–

712

76.

Metascreen Writing Committee

;

Bonadonna

RC

,

Cucinotta

D

,

Fedele

D

,

Riccardi

G

,

Tiengo

A

.

The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey

.

Diabetes Care

2006

;

29

:

2701

–

2707

77.

Oellgaard

J

,

Gaede

P

,

Rossing

P

,

Persson

F

,

Parving

H-H

,

Pedersen

O

.

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits

.

Kidney Int

2017

;

91

:

982

–

988

78.

Sandholm

N

,

Van Zuydam

N

,

Ahlqvist

E

, et al,

The FinnDiane Study Group

;

Tuomilehto

J

,

Lyssenko

V

,

McKeigue

PM

, et al,

The DCCT/EDIC Study Group

;

Florez

JC

,

Hirschhorn

JN

,

Maxwell

AP

,

GENIE Consortium

;

Dunger

D

,

Cobelli

C

,

Colhoun

HM

, et al,

SUMMIT Consortium

.

The genetic landscape of renal complications in type 1 diabetes

.

J Am Soc Nephrol

2017

;

28

:

557

–

574

79.

van Zuydam

NR

,

Ahlqvist

E

,

Sandholm

N

, et al

A genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes

.

Diabetes

2018

;

67

:

1414

–

1427

80.

Seaquist

ER

,

Goetz

FC

,

Rich

S

,

Barbosa

J

.

Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy

.

N Engl J Med

1989

;

320

:

1161

–

1165

81.

Imperatore

G

,

Nelson

RG

.

Genetic susceptibility to nephropathy in Pima Indians with type 2 diabetes mellitus

.

Nephrology

1998

;

4

(

Suppl. 2

):

S34

–

S39

82.

Fagerudd

JA

,

Tarnow

L

,

Jacobsen

P

, et al

Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients

.

Diabetes

1998

;

47

:

439

–

444

83.

Thorn

LM

,

Forsblom

C

,

Fagerudd

J

,

Pettersson-Fernholm

K

,

Kilpikari

R

,

Groop

P-H

;

FinnDiane Study Group

.

Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy

.

Diabetes Care

2007

;

30

:

1162

–

1167

84.

Wuttke

M

,

Li

Y

,

Li

M

, et al

A catalog of genetic loci associated with kidney function from analyses of a million individuals

.

Nat Genet

2019

;

51

:

957

–

972

85.

Keating

ST

,

van Diepen

JA

,

Riksen

NP

,

El-Osta

A

.

Epigenetics in diabetic nephropathy, immunity and metabolism

.

Diabetologia

2018

;

61

:

6

–

20

86.

Allawi

J

,

Rao

PV

,

Gilbert

R

, et al

Microalbuminuria in non-insulin-dependent diabetes: its prevalence in Indian compared with Europid patients

.

Br Med J (Clin Res Ed)

1988

;

296

:

462

–

464

87.

Dreyer

G

,

Hull

S

,

Aitken

Z

,

Chesser

A

,

Yaqoob

MM

.

The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease

.

QJM

2009

;

102

:

261

–

269

88.

Sinha

SK

,

Shaheen

M

,

Rajavashisth

TB

,

Pan

D

,

Norris

KC

,

Nicholas

SB

.

Association of race/ethnicity, inflammation, and albuminuria in patients with diabetes and early chronic kidney disease

.

Diabetes Care

2014

;

37

:

1060

–

1068

89.

Nelson

RG

,

Knowler

WC

,

Pettitt

DJ

,

Hanson

RL

,

Bennett

PH

.

Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM

.

Diabetes Care

1995

;

18

:

182

–

187

90.

Joshy

G

,

Dunn

P

,

Fisher

M

,

Lawrenson

R

.

Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission rate for renal complications, and incidence of end-stage renal disease and renal death

.

Diabetologia

2009

;

52

:

1474

–

1478

91.

Collins

VR

,

Dowse

GK

,

Finch

CF

,

Zimmet

PZ

,

Linnane

AW

.

Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru

.

Diabetes

1989

;

38

:

1602

–

1610

92.

TODAY Study Group

.

Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial

.

Diabetes Care

2013

;

36

:

1735

–

1741

93.

Dart

AB

,

Sellers

EA

,

Martens

PJ

,

Rigatto

C

,

Brownell

MD

,

Dean

HJ

.

High burden of kidney disease in youth-onset type 2 diabetes

.

Diabetes Care

2012

;

35

:

1265

–

1271

94.

Dyck

RF

,

Jiang

Y

,

Osgood

ND

.

The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes

.

Can J Diabetes

2014

;

38

:

237

–

243

95.

Chan

JC

,

Lau

ES

,

Luk

AO

, et al

Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis

.

Am J Med

2014

;

127

:

616

–

624

96.

Sellers

EA

,

Blydt-Hansen

TD

,

Dean

HJ

,

Gibson

IW

,

Birk

PE

,

Ogborn

M

.

Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes

.

Diabetes Care

2009

;

32

:

786

–

790

97.

Murussi

M

,

Campagnolo

N

,

Beck

MO

,

Gross

JL

,

Silveiro

SP

.

High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study

.

Diabet Med

2007

;

24

:

1136

–

1142

98.

Rossing

P

,

Hougaard

P

,

Parving

H-H

.

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study

.

Diabetes Care

2002

;

25

:

859

–

864

99.

de Zeeuw

D

,

Ramjit

D

,

Zhang

Z

, et al

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL

.

Kidney Int

2006

;

69

:

1675

–

1682

100.

Babazono

T

,

Nyumura

I

,

Toya

K

, et al

Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients

.

Diabetes Care

2009

;

32

:

1518

–

1520

101.

Zoppini

G

,

Targher

G

,

Chonchol

M

, et al

Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function

.

Clin J Am Soc Nephrol

2012

;

7

:

401

–

408

102.

Rossing

P

,

Hommel

E

,

Smidt

UM

,

Parving

H-H

.

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

.

Diabetologia

1994

;

37

:

511

–

516

103.

Heerspink

HJL

,

Greene

T

,

Tighiouart

H

, et al;

Chronic Kidney Disease Epidemiology Collaboration

.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

.

Lancet Diabetes Endocrinol

2019

;

7

:

128

–

139

104.

Gordin

D

,

Hiilesmaa

V

,

Fagerudd

J

, et al;

FinnDiane Study Group

.

Preeclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women

.

Diabetologia

2007

;

50

:

516

–

522

105.

Shultis

WA

,

Weil

EJ

,

Looker

HC

, et al

Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes

.

Diabetes Care

2007

;

30

:

306

–

311

106.

Tahrani

AA

,

Ali

A

,

Raymond

NT

, et al

Obstructive sleep apnea and diabetic nephropathy: a cohort study

.

Diabetes Care

2013

;

36

:

3718

–

3725

107.

Targher

G

,

Bertolini

L

,

Rodella

S

, et al

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

.

Diabetologia

2008

;

51

:

444

–

450

108.

Targher

G

,

Mantovani

A

,

Pichiri

I

, et al

Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes

.

Diabetes Care

2014

;

37

:

1729

–

1736

109.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group

.

KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease

.

Kidney Int Suppl

2013

;

3

:

1

–

150

110.

Rossing

P

,

Persson

F

,

Frimodt-Moller

M

,

Hansen

TW

.

Linking kidney and cardiovascular complications in diabetes: impact on prognostication and treatment: the 2019 Edwin Bierman Award Lecture

.

Diabetes

2021

;

70

:

39

–

50

111.

de Zeeuw

D

,

Remuzzi

G

,

Parving

H-H

, et al

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

.

Circulation

2004

;

110

:

921

–

927

112.

Coresh

J

,

Heerspink

HJL

,

Sang

Y

, et al;

Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration

.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

.

Lancet Diabetes Endocrinol

2019

;

7

:

115

–

127

113.

Desai

AS

,

Toto

R

,

Jarolim

P

, et al

Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD

.

Am J Kidney Dis

2011

;

58

:

717

–

728

114.

Galsgaard

J

,

Persson

F

,

Hansen

TW

, et al

Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy

.

Kidney Int

2017

;

92

:

1242

–

1248

115.

Good

DM

,

Zurbig

P

,

Argiles

A

, et al

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease

.

Mol Cell Proteomics

2010

;

9

:

2424

–

2437

116.

Zurbig

P

,

Jerums

G

,

Hovind

P

, et al

Urinary proteomics for early diagnosis in diabetic nephropathy

.

Diabetes

2012

;

61

:

3304

–

3313

117.

Tofte

N

,

Lindhardt

M

,

Adamova

K

, et al;

PRIORITY Investigators

.

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

.

Lancet Diabetes Endocrinol

2020

;

8

:

301

–

312

118.

Amdur

RL

,

Feldman

HI

,

Gupta

J

, et al;

CRIC Study Investigators

.

Inflammation and progression of CKD: the CRIC study

.

Clin J Am Soc Nephrol

2016

;

11

:

1546

–

1556

119.

Niewczas

MA

,

Pavkov

ME

,

Skupien

J

, et al

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes

.

Nat Med

2019

;

25

:

805

–

813

120.

Pilemann-Lyberg

S

,

Hansen

TW

,

Tofte

N

, et al

Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes

.

Diabetes Care

2019

;

42

:

1088

–

1094

121.

Doria

A

,

Galecki

AT

,

Spino

C

, et al;

PERL Study Group

.

Serum urate lowering with allopurinol and kidney function in type 1 diabetes

.

N Engl J Med

2020

;

382

:

2493

–

2503

122.

Ahola

AJ

,

Sandholm

N

,

Forsblom

C

,

Harjutsalo

V

,

Dahlstrom

E

,

Groop

P-H

;

FinnDiane Study Group

.

The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes

.

Kidney Int

2017

;

91

:

1178

–

1185

123.

Stack

AG

,

Dronamraju

N

,

Parkinson

J

, et al

Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial

.

Am J Kidney Dis

2021

;

77

:

481

–

489

124.

Kjaer

LK

,

Cejvanovic

V

,

Henriksen

T

, et al

Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoGuo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study

.

Diabetes Care

2017

;

40

:

1771

–

1778

125.

Komorowsky

CV

,

Brosius

FC

III,

Pennathur

S

,

Kretzler

M

.

Perspectives on systems biology applications in diabetic kidney disease

.

J Cardiovasc Transl Res

2012

;

5

:

491

–

508

126.

Brosius

FC

,

Tuttle

KR

,

Kretzler

M

.

JAK inhibition in the treatment of diabetic kidney disease

.

Diabetologia

2016

;

59

:

1624

–

1627

127.

Pena

MJ

,

Heerspink

HJL

,

Hellemons

ME

, et al

Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus

.

Diabet Med

2014

;

31

:

1138

–

1147

128.

Solini

A

,

Manca

ML

,

Penno

G

,

Pugliese

G

,

Cobb

JE

,

Ferrannini

E

.

Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics

.

J Clin Endocrinol Metab

2016

;

101

:

696

–

704

129.

Sharma

K

,

Karl

B

,

Mathew

AV

, et al

Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease

.

J Am Soc Nephrol

2013

;

24

:

1901

–

1912

130.

Niewczas

MA

,

Sirich

TL

,

Mathew

AV

, et al

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study

.

Kidney Int

2014

;

85

:

1214

–

1224

131.

Tofte

N

,

Suvitaival

T

,

Trost

K

, et al

Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes

.

Front Endocrinol (Lausanne)

2019

;

10

:

818

132.

Parving

H-H

,

Mauer

M

,

Fioretto

P

,

Rossing

P

,

Ritz

E

. Diabetic nephropathy. In

Brenner and Rector's the Kidney

. 9th ed.

Taal

MW

,

Chertow

GM

,

Marsden

PA

,

Skorecki

K

,

Yu

ASL

,

Brenner

BM

, Eds.

Philadelphia, PA

,

Elsevier

,

2012

, p.

1411

–

1454

133.

Perkins

BA

,

Ficociello

LH

,

Silva

KH

,

Finkelstein

DM

,

Warram

JH

,

Krolewski

AS

.

Regression of microalbuminuria in type 1 diabetes

.

N Engl J Med

2003

;

348

:

2285

–

2293

134.

Hovind

P

,

Tarnow

L

,

Rossing

P

, et al

Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study

.

BMJ

2004

;

328

:

1105

135.

Gaede

P

,

Tarnow

L

,

Vedel

P

,

Parving

H-H

,

Pedersen

O

.

Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria

.

Nephrol Dial Transplant

2004

;

19

:

2784

–

2788

136.

Solini

A

,

Penno

G

,

Bonora

E

, et al;

Renal Insufficiency And Cardiovascular Events (RIACE) Study Group

.

Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study

2012

;

35

:

143

–

149

137.

Critselis

E

,

Vlahou

A

,

Stel

VS

,

Morton

RL

.

Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion

.

Nephrol Dial Transplant

2018

;

33

:

441

–

449

138.

Tuttle

KR

,

Alicic

RZ

,

Duru

OK

, et al

Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry

.

JAMA Netw Open

2019

;

2

:

e1918169

139.

Khan

MAB

,

Hashim

MJ

,

King

JK

,

Govender

RD

,

Mustafa

H

,

Al Kaabi

J

.

Epidemiology of type 2 diabetes: global burden of disease and forecasted trends

.

J Epidemiol Glob Health

2020

;

10

:

107

–

111

140.

Whaley-Connell

A

,

Sowers

JR

.

Basic science: pathophysiology: the cardiorenal metabolic syndrome

.

J Am Soc Hypertens

2014

;

8

:

604

–

606

141.

Arnold

SV

,

Kosiborod

M

,

Wang

J

,

Fenici

P

,

Gannedahl

G

,

LoCasale

RJ

.

Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry

.

Diabetes Obes Metab

2018

;

20

:

2000

–

2003

142.

Ronco

C

,

Haapio

M

,

House

AA

,

Anavekar

N

,

Bellomo

R

.

Cardiorenal syndrome

.

J Am Coll Cardiol

2008

;

52

:

1527

–

1539

143.

Dokken

BB

.

The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids

.

Diabetes Spectr

2008

;

21

:

160

–

165

144.

Kannel

WB

,

McGee

DL

.

Diabetes and cardiovascular disease: the Framingham study

.

JAMA

1979

;

241

:

2035

–

2038

145.

Gore

MO

,

Patel

MJ

,

Kosiborod

M

, et al;

National Registry of Myocardial Infarction Investigators

.

Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006

.

Circ Cardiovasc Qual Outcomes

2012

;

5

:

791

–

797

146.

Petrie

JR

,

Guzik

TJ

,

Touyz

RM

.

Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms

.

Can J Cardiol

2018

;

34

:

575

–

584

147.

Grisanti

LA

.

Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes

.

Front Physiol

2018

;

9

:

1669

148.

Nichols

GA

,

Hillier

TA

,

Erbey

JR

,

Brown

JB

.

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors

.

Diabetes Care

2001

;

24

:

1614

–

1619

149.

Meagher

P

,

Adam

M

,

Civitarese

R

,

Bugyei-Twum

A

,

Connelly

KA

.

Heart failure with preserved ejection fraction in diabetes: mechanisms and management

.

Can J Cardiol

2018

;

34

:

632

–

643

150.

Jia

G

,

Hill

MA

,

Sowers

JR

.

Diabetic cardiomyopathy

.

Circ Res

2018

;

122

:

624

–

638

151.

Kenny

HC

,

Abel

ED

.

Heart failure in type 2 diabetes mellitus

.

Circ Res

2019

;

124

:

121

–

141

152.

Jensen

MT

,

Fung

K

,

Aung

N

, et al

Changes in cardiac morphology and function in individuals with diabetes mellitus

.

Circ Cardiovasc Imaging

2019

;

12

:

e009476

153.

Gheith

O

,

Farouk

N

,

Nampoory

N

,

Halim

MA

,

Al-Otaibi

T

.

Diabetic kidney disease: world wide difference of prevalence and risk factors

.

J Nephropharmacol

2016

;

5

:

49

–

56

154.

Piccoli

GB

,

Grassi

G

,

Cabiddu

G

, et al

Diabetic kidney disease: a syndrome rather than a single disease

.

Rev Diabet Stud

2015

;

12

:

87

–

109

155.

Brown

JM

,

Everett

BM

.

Cardioprotective diabetes drugs: what cardiologists need to know

.

Cardiovasc Endocrinol Metab

2019

;

8

:

96

–

105

156.

McGuire

DK

,

Shih

WJ

,

Cosentino

F

, et al

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis

.

JAMA Cardiol

2021

;

6

:

148

–

158

157.

American Diabetes Association

.

10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2021

.

Diabetes Care

2021

;

44

(

Suppl. 1

):

S125

–

S150

158.

Pugliese

G

,

Penno

G

,

Natali

A

, et al;

Italian Diabetes Society; Italian Society of Nephrology

.

Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function.”

.

J Nephrol

2020

;

33

:

9

–

35

159.

Wiviott

SD

,

Raz

I

,

Bonaca

MP

, et al;

DECLARE–TIMI 58 Investigators

.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

.

N Engl J Med

2019

;

380

:

347

–

357

160.

Mosenzon

O

,

Wiviott

SD

,

Cahn

A

, et al

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

.

Lancet Diabetes Endocrinol

2019

;

7

:

606

–

617

161.

Neal

B

,

Perkovic

V

,

Mahaffey

KW

, et al;

CANVAS Program Collaborative Group

.

Canagliflozin and cardiovascular and renal events in type 2 diabetes

.

N Engl J Med

2017

;

377

:

644

–

657

162.

Neuen

BL

,

Young

T

,

Heerspink

HJL

, et al

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

.

Lancet Diabetes Endocrinol

2019

;

7

:

845

–

854

162a.

U.S. Food and Drug Administration

.

FDA approves treatment for chronic kidney disease: approval is first to cover many causes of disease

.

Available from https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease. Accessed 5 May 2021

163.

Pitt

B

,

Pfeffer

MA

,

Assmann

SF

, et al;

TOPCAT Investigators

.

Spironolactone for heart failure with preserved ejection fraction

.

N Engl J Med

2014

;

370

:

1383

–

1392

164.

de Denus

S

,

O'Meara

E

,

Desai

AS

, et al

Spironolactone metabolites in TOPCAT: new insights into regional variation

.

N Engl J Med

2017

;

376

:

1690

–

1692

165.

Alicic

RZ

,

Rooney

MT

,

Tuttle

KR

.

Diabetic kidney disease: challenges, progress, and possibilities

.

Clin J Am Soc Nephrol

2017

;

12

:

2032

–

2045

166.

Centers for Disease Control and Prevention

.

National Diabetes Statistics Report, 2020

.

Atlanta, GA

,

Centers for Disease Control and Prevention, U.S. Department of Health and Human Services

,

2020

167.

Tuttle

KR

,

Bakris

GL

,

Bilous

RW

, et al

Diabetic kidney disease: a report from an ADA consensus conference

.

Am J Kidney Dis

2014

;

64

:

510

–

533

168.

American Diabetes Association

.

11. Microvascular complications and foot care: Standards of Medical Care in Diabetes—2021

.

Diabetes Care

2021

;

44

(

Suppl. 1

):

S151

–

S167

169.

Shlipak

MG

,

Tummalapalli

SL

,

Boulware

LE

, et al;

Conference Participants

.

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference

.

Kidney Int

2021

;

99

:

34

–

47

170.

Nolte

E

,

McKee

M

.

Variations in amenable mortality: trends in 16 high-income nations

.

Health Policy

2011

;

103

:

47

–

52

171.

Schroeder

SA

.

Shattuck Lecture. We can do better: improving the health of the American people

.

N Engl J Med

2007

;

357

:

1221

–

1228

172.

Hall

YN

.

Social determinants of health: addressing unmet needs in nephrology

.

Am J Kidney Dis

2018

;

72

:

582

–

591

173.

Norton

JM

,

Moxey-Mims

MM

,

Eggers

PW

, et al

Social determinants of racial disparities in CKD

.

J Am Soc Nephrol

2016

;

27

:

2576

–

2595

174.

Nicholas

SB

,

Kalantar-Zadeh

K

,

Norris

KC

.

Socioeconomic disparities in chronic kidney disease

.

Adv Chronic Kidney Dis

2015

;

22

:

6

–

15

175.

Bailey

ZD

,

Feldman

JM

,

Bassett

MT

.

How structural racism works: racist policies as a root cause of U.S. racial health inequities

.

N Engl J Med

2021

;

384

:

768

–

773

176.

Bailey

ZD

,

Krieger

N

,

Agénor

M

,

Graves

J

,

Linos

N

,

Bassett

MT

.

Structural racism and health inequities in the USA: evidence and interventions

.

Lancet

2017

;

389

:

1453

–

1463

177.

Moosa

MR

,

Norris

KC

.

Sustainable social development: tackling poverty to achieve kidney health equity

.

Nat Rev Nephrol

2021

;

17

:

3

–

4

178.

Laster

M

,

Shen

JI

,

Norris

KC

.

Kidney disease among African Americans: a population perspective

.

Am J Kidney Dis

2018

;

72

(

Suppl. 1

):

S3

–

S7

179.

Crews

DC

,

Pfaff

T

,

Powe

NR

.

Socioeconomic factors and racial disparities in kidney disease outcomes

.

Semin Nephrol

2013

;

33

:

468

–

475

180.

Geronimus

AT

,

Hicken

M

,

Keene

D

,

Bound

J

.

“Weathering” and age patterns of allostatic load scores among Blacks and Whites in the United States

.

Am J Public Health

2006

;

96

:

826

–

833

181.

Marmot

M

,

Friel

S

,

Bell

R

,

Houweling

TA

,

Taylor

S

;

Commission on Social Determinants of Health

.

Closing the gap in a generation: health equity through action on the social determinants of health

.

Lancet

2008

;

372

:

1661

–

1669

182.

Wen

M

,

Browning

CR

,

Cagney

KA

.

Poverty, affluence, and income inequality: neighborhood economic structure and its implications for health

.

Soc Sci Med

2003

;

57

:

843

–

860

183.

Payne

RK

,

Blair

T

.

A Framework for Understanding Poverty.

Highlands, TX

,

aha! Process

,

2005

.

184.

Duru

OK

,

Middleton

T

,

Tewari

MK

,

Norris

K

.

The Landscape of diabetic kidney disease in the United States

.

Curr Diab Rep

2018

;

18

:

14

185.

De la Fuente

F

,

Saldías

MA

,

Cubillos

C

, et al

Green space exposure association with type 2 diabetes mellitus, physical activity, and obesity: a systematic review

.

Int J Environ Res Public Health

2020

;

18

:

97

186.

Eberly

LA

,

Yang

L

,

Eneanya

ND

, et al

Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US

.

JAMA Netw Open

2021

;

4

:

e216139

187.

Oppenheimer

GM

.

Paradigm lost: race, ethnicity, and the search for a new population taxonomy

.

Am J Public Health

2001

;

91

:

1049

–

1055

188.

Genovese

G

,

Friedman

DJ

,

Ross

,

MD

, et al

Association of trypanolytic ApoL1 variants with kidney disease in African Americans

.

Science

2010

;

329

:

841

–

845

189.

Umeukeje

EM

,

Young

BA

.

Genetics and ESKD disparities in African Americans

.

Am J Kidney Dis

2019

;

74

:

811

–

821

190.

Gutiérrez

OM

,

Irvin

MR

,

Chaudhary

NS

, et al

APOL1 nephropathy risk variants and incident cardiovascular disease events in community-dwelling Black adults

.

Circ Genom Precis Med

2018

;

11

:

e002098

191.

Palmer

ND

,

Freedman

BI

.

APOL1 and progression of nondiabetic nephropathy

.

J Am Soc Nephrol

2013

;

24

:

1344

–

1346

192.

Levey

AS

,

Bosch

JP

,

Lewis

JB

,

Greene

T

,

Rogers

N

,

Roth

D

.

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

.

Ann Intern Med

1999

;

130

:

461

–

470

193.

Levey

AS

,

Stevens

LA

,

Schmid

CH

, et al;

CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)

.

A new equation to estimate glomerular filtration rate

.

Ann Intern Med

2009

;

150

:

604

–

612

194.

Norris

KC

,

Eneanya

ND

,

Boulware

LE

.

Removal of race from estimates of kidney function: first, do no harm

.

JAMA

2021

;

325

:

135

–

137

195.

Subramanian

SV

,

Jones

K

,

Kaddour

A

,

Krieger

N

.

Revisiting Robinson: the perils of individualistic and ecologic fallacy

.

Int J Epidemiol

2009

;

38

:

342–360; author reply 370

–

373

196.

American Diabetes Association

.

1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes—2021

.

Diabetes Care

2021

;

44

(

Suppl. 1

):

S7

–

S14

197.

Pagels

AA

,

Hylander

B

,

Alvarsson

M

.

A multi-dimensional support programme for patients with diabetic kidney disease

.

J Ren Care

2015

;

41

:

187

–

194

198.

Tuot

DS

,

Diamantidis

CJ

,

Corbett

CF

, et al

The last mile: translational research to improve CKD outcomes

.

Clin J Am Soc Nephrol

2014

;

9

:

1802

–

1805

199.

Narva

AS

,

Norton

JM

,

Boulware

LE

.

Educating patients about CKD: the path to self-management and patient-centered care

.

Clin J Am Soc Nephrol

2016

;

11

:

694

–

703

200.

Goldstein

K

,

Briggs

M

,

Oleynik

V

, et al

Using digital media to promote kidney disease education

.

Adv Chronic Kidney Dis

2013

;

20

:

364

–

369

201.

Tuttle

KR

,

Bakris

GL

,

Bilous

RW

, et al

Diabetic kidney disease: a report from an ADA consensus conference

.

Diabetes Care

2014

;

37

:

2864

–

2883

202.

Afkarian

M

,

Zelnick

LR

,

Hall

YN

, et al

Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014

.

JAMA

2016

;

316

:

602

–

610

203.

de Boer

IH

,

Rue

TC

,

Hall

YN

,

Heagerty

PJ

,

Weiss

NS

,

Himmelfarb

J

.

Temporal trends in the prevalence of diabetic kidney disease in the United States

.

JAMA

2011

;

305

:

2532

–

2539

204.

de Boer

IH

;

DCCT/EDIC Research Group

.

Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study

.

Diabetes Care

2014

;

37

:

24

–

30

205.

Brannick

B

,

Wynn

A

,

Dagogo-Jack

S

.

Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications

.

Exp Biol Med (Maywood)

2016

;

241

:

1323

–

1331

206.

Plantinga

LC

,

Crews

DC

,

Coresh

J

, et al;

CDC CKD Surveillance Team

.

Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes

.

Clin J Am Soc Nephrol

2010

;

5

:

673

–

682

207.

United States Renal Data System

.

Annual Data Report: Epidemiology of Kidney Disease in the United States

.

Bethesda, MD

,

National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

,

2016

208.

Fox

CS

,

Matsushita

K

,

Woodward

M

, et al;

Chronic Kidney Disease Prognosis Consortium

.

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

.

Lancet

2012

;

380

:

1662

–

1673

209.

Groop

P-H

,

Thomas

MC

,

Moran

JL

, et al;

FinnDiane Study Group

.

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

.

Diabetes

2009

;

58

:

1651

–

1658

210.

Kramer

HJ

,

Nguyen

QD

,

Curhan

G

,

Hsu

C-Y

.

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus

.

JAMA

2003

;

289

:

3273

–

3277

211.

Molitch

ME

,

Steffes

M

,

Sun

W

, et al;

Epidemiology of Diabetes Interventions and Complications Study Group

.

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study

.

Diabetes Care

2010

;

33

:

1536

–

1543

212.

Centers for Disease Control and Prevention

.

Chronic kidney disease in the United States, 2021

.

Available from https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html. Accessed 14 April 2021

213.

Hemmelgarn

BR

,

James

MT

,

Manns

BJ

, et al

Rates of treated and untreated kidney failure in older vs younger adults

.

JAMA

2012

;

307

:

2507

–

2715

214.

Wouters

OJ

,

O'Donoghue

DJ

,

Ritchie

J

,

Kanavos

PG

,

Narva

AS

.

Early chronic kidney disease: diagnosis, management and models of care

.

Nat Rev Nephrol

2015

;

11

:

491

–

502

215.

Yarnoff

BO

,

Hoerger

TJ

,

Simpson

SK

, et al;

Centers for Disease Control and Prevention CKD Initiative

.

The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease

.

BMC Nephrol

2017

;

18

:

85

216.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group

.

KDIGO 2020 clinical practice guidelines for diabetes management in chronic kidney disease

.

Kidney Int

2020

;

98

(

4 Suppl.

)

S1

–

S115

217.

de Boer

IH

,

Caramori

ML

,

Chan

JCN

, et al

Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment

.

Kidney Int

2020

;

98

:

839

–

848

218.

Dagogo-Jack

S

. Complications of diabetes mellitus. In

Scientific American Medicine

.

Singh

AK

, Ed.

Hamilton, Ontario, Canada

,

Decker Intellectual Properties

,

2015

219.

Rossing

P

,

Rossing

K

,

Gaede

P

,

Pedersen

O

,

Parving

H-H

.

Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy

.

Diabetes Care

2006

;

29

:

1024

–

1030

220.

Naresh

CN

,

Hayen

A

,

Weening

A

,

Craig

JC

,

Chadban

SJ

.

Day-to-day variability in spot urine albumin-creatinine ratio

.

Am J Kidney Dis

2013

;

62

:

1095

–

1101

221.

Gomes

MB

,

Gonçalves

MF

.

Is there a physiological variability for albumin excretion rate? Study in patients with diabetes type 1 and nondiabetic individuals

.

Clin Chim Acta

2001

;

304

:

117

–

123

222.

Dagogo-Jack

S

,

Egbuonu

N

,

Edeoga

C

.

Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk

.

Med Princ Pract

2010

;

19

:

167

–

175

223.

Klahr

S

,

Levey

AS

,

Beck

GJ

, et al;

Modification of Diet in Renal Disease Study Group

.

The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease

.

N Engl J Med

1994

;

330

:

877

–

884

224.

Murray

DP

,

Young

L

,

Waller

J

, et al

Is dietary protein intake predictive of 1-year mortality in dialysis patients?

Am J Med Sci

2018

;

356

:

234

–

243

225.

Mills

KT

,

Chen

J

,

Yang

W

, et al;

Chronic Renal Insufficiency Cohort (CRIC) Study Investigators

.

Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease

.

JAMA

2016

;

315

:

2200

–

2210

226.

Nilsson

E

,

Gasparini

A

,

Arnlov

J

, et al

Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system

.

Int J Cardiol

2017

;

245

:

277

–

284

227.

Dagogo-Jack

S

. Glycemic control and chronic diabetes complications. In

Therapy for Diabetes Mellitus and Related Disorders

. 6th ed.

Umpierrez

GE

, Ed.

Alexandria, VA

,

American Diabetes Association

,

2014

, p.

668

–

695

228.

Writing Team for the DCCT/EDIC Research Group

.

Sustained effects of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy

.

JAMA

2003

;

290

:

2159

–

2167

229.

DCCT/EDIC Research Group

;

de Boer

IH

,

Sun

W

,

Cleary

PA

, et al

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

.

N Engl J Med

2011

;

365

:

2366

–

2376

230.

Holman

RR

,

Paul

SK

,

Bethel

MA

,

Neil

HA

,

Matthews

DR

.

Long-term follow-up after tight control of blood pressure in type 2 diabetes

.

N Engl J Med

2008

;

359

:

1565

–

1576

231.

Long

AN

,

Dagogo-Jack

S

.

The comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection

.

J Clin Hypertens (Greenwich)

2011

;

13

:

244

–

251

232.

Dagogo-Jack

S

.

Preventing diabetes-related morbidity and mortality in the primary care setting

.

J Natl Med Assoc

2002

;

94

:

549

–

560

233.

UK Prospective Diabetes Study Group

.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

.

BMJ

1998

;

317

:

703

–

713

234.

Leehey

DJ

,

Zhang

JH

,

Emanuele

NV

, et al;

VA NEPHRON-D Study Group

.

BP and renal outcomes in diabetic kidney disease: the Veterans Affairs Nephropathy in Diabetes Trial

.

Clin J Am Soc Nephrol

2015

;

10

:

2159

–

2169

235.

Cushman

WC

,

Evans

GW

,

Byington

RP

, et al;

ACCORD Study Group

.

Effects of intensive blood pressure control in type 2 diabetes mellitus

.

N Engl J Med

2010

;

362

:

1575

–

1585

236.

Lewis

EJ

,

Hunsicker

LG

,

Bain

RP

,

Rohde

RD

;

The Collaborative Study Group

.

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

.

N Engl J Med

1993

;

329

:

1456

–

1462

237.

Fried

LF

,

Emanuele

N

,

Zhang

JH

, et al;

VA NEPHRON-D Investigators

.

Combined angiotensin inhibition for the treatment of diabetic nephropathy

.

N Engl J Med

2013

;

369

:

1892

–

1903

238.

Williams

B

,

MacDonald

TM

,

Morant

S

, et al;

British Hypertension Society's PATHWAY Studies Group

.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

.

Lancet

2015

;

386

:

2059

–

2068

239.

Bakris

GL

,

Agarwal

R

,

Chan

JC

, et al;

Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group

.

Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial

.

JAMA

2015

;

314

:

884

–

894

240.

Moen

MF

,

Zhan

M

,

Hsu

VD

, et al

Frequency of hypoglycemia and its significance in chronic kidney disease

.

Clin J Am Soc Nephrol

2009

;

4

:

1121

–

1127

241.

Chu

PY

,

Hackstadt

AJ

,

Chipman

J

, et al

Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas

.

Diabetes Care

2020

;

43

:

1462

–

1470

242.

U.S. Food and Drug Administration

.

FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function

.

Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain. Accessed 11 August 2020

243.

Lalau

J-D

,

Kajbaf

F

,

Bennis

Y

,

Hurtel-Lemaire

A-S

,

Belpaire

F

,

De Broe

ME

.

Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4

.

Diabetes Care

2018

;

41

:

547

–

553

244.

Diabetes Control and Complications Trial Research Group

;

Nathan

DM

,

Genuth

S

,

Lachin

J

, et al

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus

.

N Engl J Med

1993

;

329

:

977

–

986

245.

Murray

P

,

Chune

GW

,

Raghavan

VA

.

Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials

.

Curr Atheroscler Rep

2010

;

12

:

432

–

439

246.

Zoungas

S

,

Arima

H

,

Gerstein

HC

, et al;

Collaborators on Trials of Lowering Glucose (CONTROL) Group

.

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

.

Lancet Diabetes Endocrinol

2017

;

5

:

431

–

437

247.

Agrawal

L

,

Azad

N

,

Bahn

GD

, et al;

VADT Study Group

.

Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)

.

Diabetologia

2018

;

61

:

295

–

299

248.

Zaccardi

F

,

Dhalwani

NN

,

Webb

DR

,

Davies

MJ

,

Khunti

K

.

Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates

.

Diabetologia

2018

;

61

:

1592

–

1602

249.

Hanefeld

M

,

Duetting

E

,

Bramlage

P

.

Cardiac implications of hypoglycaemia in patients with diabetes: a systematic review

.

Cardiovasc Diabetol

2013

;

12

:

135

250.

Cherney

DZI

,

Perkins

BA

,

Soleymanlou

N

, et al

Renal hemodynamic effect of sodium glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

.

Circulation

2014

;

129

:

587

–

597

251.

Zelniker

TA

,

Braunwald

E

.

Cardiac and renal effects of sodium–glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review

.

J Am Coll Cardiol

2018

;

72

:

1845

–

1855

252.

Woods

TC

,

Satou

R

,

Miyata

K

, et al

Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus

.

Am J Nephrol

2019

;

49

:

331

–

342

253.

Heerspink

HJL

,

Perco

P

,

Mulder

S

, et al

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

.

Diabetologia

2019

;

62

:

1154

–

1166

254.

Yaribeygi

H

,

Butler

AE

,

Atkin

SL

,

Katsiki

N

,

Sahebkar

A

.

Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways

.

J Cell Physiol

2018

;

234

:

223

–

230

255.

Arjun

S

,

Bell

RM

.

SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?

Cardiovasc Res

2019

;

115

:

1454

–

1456

256.

Jardine

MJ

,

Mahaffey

KW

,

Neal

B

, et al;

CREDENCE Study Investigators

.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

.

Am J Nephrol

2017

;

46

:

462

–

472

257.

Packer

M

,

Anker

SD

,

Butler

J

, et al;

EMPEROR-Reduced Trial Investigators

.

Cardiovascular and renal outcomes with empagliflozin in heart failure

.

N Engl J Med

2020

;

383

:

1413

–

1424

258.

Boehringer Ingelheim

.

Invokana (canagliflozin) prescribing information

,

2020

.

Available from https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf.. Accessed 10 March 2021

259.

AstraZeneca

.

Farxiga (dapagliflozin) prescribing information

,

2020

.

Available from https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf. Accessed 10 March 2021

260.

Rosenwasser

RF

,

Sultan

S

,

Sutton

D

,

Choksi

R

,

Epstein

BJ

.

SGLT-2 inhibitors and their potential in the treatment of diabetes

.

Diabetes Metab Syndr Obes

2013

;

6

:

453

–

467

261.

Merck

.

Steglatro (ertugliflozin) prescribing information

.

Available from https://www.merck.com/product/usa/pi_circulars/s/steglatro/steglatro_pi.pdf. Accessed 10 March 2021

262.

Zelniker

TA

,

Wiviott

SD

,

Raz

I

, et al

Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus

.

Circulation

2019

;

139

:

2022

–

2031

263.

.

A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW)

.

Available from https://clinicaltrials.gov/ct2/show/NCT03819153. Accessed 10 March 2021

264.

Bakris

GL

,

Weir

MR

.

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

Arch Intern Med

2000

;

160

:

685

–

693

265.

Collard

D

,

Brouwer

TF

,

Peters

RJG

,

Vogt

L

,

van den Born

BH

.

Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus

.

Hypertension

2018

;

72

:

1337

–

1344

266.

James

MT

,

Grams

ME

,

Woodward

M

, et al;

CKD Prognosis Consortium

.

A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury

.

Am J Kidney Dis

2015

;

66

:

602

–

612

267.

Thakar

CV

,

Christianson

A

,

Himmelfarb

J

,

Leonard

AC

.

Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus

.

Clin J Am Soc Nephrol

2011

;

6

:

2567

–

2572

268.

Vassalotti

JA

,

Centor

R

,

Turner

BJ

,

Greer

RC

,

Choi

M

,

Sequist

TD

;

National Kidney Foundation Kidney Disease Outcomes Quality Initiative

.

Practical approach to detection and management of chronic kidney disease for the primary care clinician

.

Am J Med

2016

;

129

:

153

–

162.e7

269.

Guariguata

L

,

Whiting

DR

,

Hambleton

I

,

Beagley

J

,

Linnenkamp

U

,

Shaw

JE

.

Global estimates of diabetes prevalence for 2013 and projections for 2035

.

Diabetes Res Clin Pract

2014

;

103

:

137

–

149

270.

International Diabetes Federation

.

Diabetes Atlas

. 9th ed.

Brussels, Belgium

,

International Diabetes Federation

,

2019

271.

Liyanage

T

,

Ninomiya

T

,

Jha

V

, et al

Worldwide access to treatment for end-stage kidney disease: a systematic review

.

Lancet

2015

;

385

:

1975

–

1982

272.

Levin

A

,

Tonelli

M

,

Bonventre

J

, et al;

ISN Global Kidney Health Summit Participants

.

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

.

Lancet

2017

;

390

:

1888

–

1917

273.

Bakris

GL

,

Molitch

M

.

Microalbuminuria as a risk predictor in diabetes: the continuing saga

.

Diabetes Care

2014

;

37

:

867

–

875

274.

Patel

RB

,

Colangelo

LA

,

Reis

JP

, et al

Association of longitudinal trajectory of albuminuria in young adulthood with myocardial structure and function in later life: Coronary Artery Risk Development in Young Adults (CARDIA) study

.

JAMA Cardiol

2020

;

5

:

184

–

192

275.

Bakris

GL

,

Weir

MR

,

Shanifar

S

, et al;

RENAAL Study Group

.

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

.

Arch Intern Med

2003

;

163

:

1555

–

1565

276.

Viberti

G

,

Wheeldon

NM

;

Microalbuminuria Reduction With Valsartar (MARVAL) Study Investigators

.

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

.

Circulation

2002

;

106

:

672

–

678

277.

American Diabetes Association

.

9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021

.

Diabetes Care

2021

;

44

(

Suppl. 1

):

S111

–

S124

278.

Hannedouche

T

,

Landais

P

,

Goldfarb

B

, et al

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure

.

BMJ

1994

;

309

:

833

–

837

279.

Bakris

GL

,

Copley

JB

,

Vicknair

N

,

Sadler

R

,

Leurgans

S

.

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

.

Kidney Int

1996

;

50

:

1641

–

1650

280.

Bakris

GL

,

Mangrum

A

,

Copley

JB

,

Vicknair

N

,

Sadler

R

.

Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans

.

Hypertension

1997

;

29

:

744

–

750

281.

Bakris

G

,

Oshima

M

,

Mahaffey

KW

, et al

Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m²: subgroup analysis of the randomized CREDENCE trial

.

Clin J Am Soc Nephrol

2020

;

15

:

1705

–

1714

282.

Mann

JFE

,

Green

D

,

Jamerson

K

, et al;

ASCEND Study Group

.

Avosentan for overt diabetic nephropathy

.

J Am Soc Nephrol

2010

;

21

:

527

–

535

283.

Packham

DK

,

Wolfe

R

,

Reutens

AT

, et al;

Collaborative Study Group

.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

.

J Am Soc Nephrol

2012

;

23

:

123

–

130

284.

Tuttle

KR

,

McGill

JB

,

Haney

DJ

,

Lin

TE

,

Anderson

PW

;

PKC-DRS, PKC-DRS 2 Study Groups

.

Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

.

Clin J Am Soc Nephrol,

2007

;

2

:

631

–

636

285.

Sharma

K

,

Ix

JH

,

Mathew

AV

, et al

Pirfenidone for diabetic nephropathy

.

J Am Soc Nephrol

2011

;

22

:

1144

–

1151

286.

Parving

H-H

,

Brenner

BM

,

McMurray

JJV

, et al;

ALTITUDE Investigators

.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

.

N Engl J Med

2012

;

367

:

2204

–

2213

287.

de Zeeuw

D

,

Akizawa

T

,

Audhya

P

, et al;

BEACON Trial Investigators

.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

.

N Engl J Med

2013

;

369

:

2492

–

2503

288.

ONTARGET Investigators

;

Yusef

S

,

Teo

KK

,

Pogue

J

, et al

Telmisartan, ramipril, or both in patients at high risk for vascular events

.

N Engl J Med

2008

;

358

:

1547

–

1559

289.

Bakris

GL

.

Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors

.

Am J Kidney Dis

2019

;

74

:

573

–

575

290.

Kraus

BJ

,

Weir

MR

,

Bakris

GL

, et al

Characterization and implications of the initial estimated glomerular filtration rate ‘dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

.

Kidney Int

2021

;

99

:

750

–

762

291.

Oshima

M

,

Jardine

MJ

,

Agarwal

R

, et al

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

.

Kidney Int

2021

;

99

:

999

–

1009

292.

Dekkers

CCJ

,

Wheeler

DC

,

Sjöström

CD

,

Stefansson

BV

,

Cain

V

,

Heerspink

HJL

.

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease

.

Nephrol Dial Transplant

2018

;

33

:

2005

–

2011

293.

Sternlicht

H

,

Bakris

GL

.

Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis

.

Curr Hypertens Rep

2019

;

21

:

12

294.

Zelniker

TA

,

Braunwald

E

.

Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review

.

J Am Coll Cardiol

2020

;

75

:

422

–

434

295.

Wilcox

CS

.

Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors

.

Hypertension

2020

;

75

:

894

–

901

296.

Packer

M

.

Mitigation of the adverse consequences of nutrient excess on the kidney: a unified hypothesis to explain the renoprotective effects of sodium-glucose cotransporter 2 inhibitors

.

Am J Nephrol

2020

;

51

:

289

–

293

297.

Herat

LY

,

Magno

AL

,

Rudnicka

C

, et al

SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection

.

JACC Basic Transl Sci

2020

;

5

:

169

–

179

298.

Heerspink

HHJ

,

Perkins

BA

,

Ficthett

DH

,

Husain

M

,

Cherney

DZI

.

Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications

.

Circulation

2016

;

134

:

752

–

772

299.

Jardine

MJ

,

Zhou

Z

,

Mchaffey

KW

, et al;

CREDENCE Study Investigators

.

Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial

.

J Am Soc Nephrol

2020

;

31

:

1128

–

1139

300.

Mayer

GJ

,

Wanner

C

,

Weir

MR

, et al

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

.

Kidney Int

2019

;

96

:

489

–

504

301.

Mahaffey

KW

,

Neal

B

,

Perkovic

V

, et al;

CANVAS Program Collaborative Group

.

Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

.

Circulation

2018

;

137

:

323

–

334

302.

Cannon

CP

,

Pratley

R

,

Dagogo-Jack

S

, et al;

VERTIS CV Investigators

.

Cardiovascular outcomes with ertugliflozin in type 2 diabetes

.

N Engl J Med

2020

;

383

:

1425

–

1435

303.

Wheeler

DC

,

Stefánsson

BV

,

Jongs

N

, et al;

DAPA-CKD Trial Committees and Investigators

.

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

.

Lancet Diabetes Endocrinol

2021

;

9

:

22

–

31

304.

Drucker

DJ

,

Nauck

MA

.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

.

Lancet

2006

;

368

:

1696

–

1705

305.

Tuttle

KR

,

Lakshmanan

MC

,

Rayner

B

, et al

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

.

Lancet Diabetes Endocrinol

2018

;

6

:

605

–

617

306.

Mann

JFE

,

Muskiet

MHA

.

Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

.

Kidney Int

2021

;

99

:

314

–

318

307.

Qiu

M

,

Ding

L-L

,

Wei

X-B

,

Liu

S-Y

,

Zhou

H-R

.

Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis

.

J Cardiovasc Pharmacol

2021

;

77

:

34

–

37

308.

Verma

S

,

McGuire

DK

,

Bain

SC

, et al

Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials

.

Diabetes Obes Metab

2020

;

22

:

2487

–

2492

309.

Yin

WL

,

Bain

SC

,

Min

T

.

The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes

.

Diabetes Ther

2020

;

11

:

835

–

844

310.

Marso

SP

,

Daniels

GH

,

Brown-Frandsen

K

, et al;

LEADER Steering Committee; LEADER Trial Investigators

.

Liraglutide and cardiovascular outcomes in type 2 diabetes

.

N Engl J Med

2016

;

375

:

311

–

322

311.

Holman

RR

,

Bethel

MA

,

Hernandez

AF

.

Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes

.

N Engl J Med

2017

;

377

:

2502

312.

.

Renal effects of treatment with empagliflozin alone or in combination with semaglutide in patients with type 2 diabetes and albuminuria (EmpaSema)

.

Available from https://clinicaltrials.gov/ct2/show/NCT04061200. Accessed 5 March 2021

313.

Hermidorff

MM

,

de Assis

LVM

,

Isoldi

MC

.

Genomic and rapid effects of aldosterone: what we know and do not know thus far

.

Heart Fail Rev

2017

;

22

:

65

–

89

314.

Sato

A

,

Hayashi

K

,

Naruse

M

,

Saruta

T

.

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

.

Hypertension

2003

;

41

:

64

–

68

315.

Agarwal

R

,

Kolkhof

P

,

Bakris

G

, et al

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

.

Eur Heart J

2021

;

42

:

152

–

161

316.

Epstein

M

,

Williams

GH

,

Weinberger

M

, et al

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

.

Clin J Am Soc Nephrol

2006

;

1

:

940

–

951

317.

Al Dhaybi

O

,

Bakris

GL

.

Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease

.

Diabetes Obes Metab

2020

;

22

(

Suppl. 1

):

69

–

76

318.

Ruilope

LM

,

Agarwal

R

,

Anker

SD

, et al;

FIGARO-DKD Study Investigators

.

Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial

.

Am J Nephrol

2019

;

50

:

345

–

356

319.

Filippatos

G

,

Anker

SD

,

Agarwal

R

, et al;

FIDELIO-DKD Investigators

.

Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

.

Circulation

2021

;

143

:

540

–

552

320.

Heerspink

HJL

,

Kohan

DE

,

de Zeeuw

D

.

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction

.

Kidney Int

2021

;

99

:

346

–

349

321.

Zhao

Y

,

Vanhoutte

PM

,

Leung

SWS

.

Vascular nitric oxide: beyond eNOS

.

J Pharmacol Sci

2015

;

129

:

83

–

94